scholarly journals Relevance of non-steroidal anti-inflammatory drugs in periodontology

2021 ◽  
Vol 26 (3) ◽  
pp. 211-222
Author(s):  
L. Yu. Orekhova ◽  
E. S. Loboda ◽  
V. G. Atrushkevich ◽  
E. V. Kosova ◽  
V. Yu. Vashneva ◽  
...  
Keyword(s):  
Design Research ◽  
Research Question ◽  
Numerical Data ◽  
Oral Diseases ◽  
Inclusion Criteria ◽  
Electronic Search ◽  
Relieve Pain ◽  
Detailed List ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Relevance. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed in dental practice to relieve pain and swelling. This study reviews information on NSAIDs, with a particular focus on those aspects that are relevant to the practice of dentistry.Materials and methods. A systematic literature search was conducted, which included studies dating from 1970 to June 2021. The search in the electronic databases e-LIBRARY.ru, Embase, Pubmed and Medline identified the studies. Articles were reviewed by meeting the inclusion and non-inclusion criteria.Results. Initially, the electronic search identified 589 studies. After reviewing the titles and abstracts, 69 potentially relevant studies were subject to full-text evaluation. Of these, 34 studies were excluded based on study design, research question, or lack of numerical data on all variables to be assessed in this study, so 35 studies with a detailed list of such data could be included in the quantitative comparison.Conclusion. The use of non-steroidal anti-inflammatory drugs may alter the inflammatory response in the treatment of oral diseases. The conducted studies have brought up questions about the effectiveness and alternative ways of NSAID delivery in dentistry, namely, dispersible formulation.

Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs

2019 ◽  
Vol 25 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Manas A. Rane ◽  
Alexander Gitin ◽  
Benjamin Fiedler ◽  
Lawrence Fiedler ◽  
Charles H. Hennekens
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Health Care Providers ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Care Providers ◽  
Relieve Pain ◽  
Gastrointestinal Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, naproxen, diclofenac, and ibuprofen, as well as selective cyclooxygenase 2 inhibitors such as celecoxib. Their use is common, as well as their side effects which cause 100 000 hospitalizations and 17 000 deaths annually. Recently, the US Food and Drug Administration strengthened its warning about the risks of cardiovascular disease (CVD) attributed to nonaspirin NSAIDs. Methods: When the sample size is large, randomization provides control of confounding not possible to achieve with any observational study. Further, observational studies and, especially, claims data have inherent confounding by indication larger than the small to moderate effects being sought. Results: While trials are necessary, they must be of sufficient size and duration and achieve high compliance and follow-up. Until then, clinicians should remain uncertain about benefits and risks of these drugs. Conclusions: Since the totality of evidence remains incomplete, health-care providers should consider all these aforementioned benefits and risks, both CVD and beyond, in deciding whether and, if so, which, NSAID to prescribe. The factors in the decision of whether and, if so, which NSAID to prescribe for relief of pain from inflammatory arthritis should not be limited to risks of CVD or gastrointestinal side effects but should also include potential benefits including improvements in overall quality of life resulting from decreases in pain or impairment from musculoskeletal pain syndromes. The judicious individual clinical decision-making about the prescription of NSAIDs to relieve pain based on all these considerations has the potential to do much more good than harm.

scholarly journals Nonsteroidal Anti-Inflammatory Drugs and Their Neuroprotective Role After an Acute Spinal Cord Injury: A Systematic Review of Animal Models

2020 ◽  
pp. 219256822090168
Author(s):  
Mark J. Lambrechts ◽  
James L. Cook
Keyword(s):  
Systematic Review ◽  
Spinal Cord ◽  
Animal Models ◽  
Motor Function ◽  
Spinal Cord Injuries ◽  
Inclusion Criteria ◽  
Improve Motor Function ◽  
Cord Injury ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Study Design: Systematic review. Objective: Spinal cord injuries (SCIs) resulting in motor deficits can be devastating injuries resulting in millions of health care dollars spent per incident. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a potential class of drugs that could improve motor function after an SCI. This systematic review utilizes PRISMA guidelines to evaluate the effectiveness of NSAIDs for SCI. Methods: PubMed/MEDLINE, CINAHL, PsycINFO, Embase, and Scopus were reviewed linking the keywords of “ibuprofen,” “meloxicam,” “naproxen,” “ketorolac,” “indomethacin,” “celecoxib,” “ATB-346,” “NSAID,” and “nonsteroidal anti-inflammatory drug” with “spinal.” Results were reviewed for relevance and included if they met inclusion criteria. The SYRCLE checklist was used to assess sources of bias. Results: A total of 2960 studies were identified in the PubMed/MEDLINE database using the above-mentioned search criteria. A total of 461 abstracts were reviewed in Scopus, 340 in CINAHL, 179 in PsycINFO, and 7632 in Embase. A total of 15 articles met the inclusion criteria. Conclusions: NSAIDs’ effectiveness after SCI is largely determined by its ability to inhibit Rho-A. NSAIDs are a promising therapeutic option in acute SCI patients because they appear to decrease cord edema and inflammation, increase axonal sprouting, and improve motor function with minimal side effects. Studies are limited by heterogeneity, small sample size, and the use of animal models, which might not replicate the therapeutic effects in humans. There are no published human studies evaluating the safety and efficacy of these drugs after a traumatic cord injury. There is a need for well-designed prospective studies evaluating ibuprofen or indomethacin after adult spinal cord injuries.

Non-steroidal anti-inflammatory drugs for heterotopic ossification prophylaxis after total hip arthroplasty

2018 ◽  
Vol 100-B (7) ◽  
pp. 915-922 ◽  
Author(s):  
M. Joice ◽  
G. I. Vasileiadis ◽  
D. F. Amanatullah
Keyword(s):  
Total Hip Arthroplasty ◽  
Heterotopic Ossification ◽  
Hip Arthroplasty ◽  
Patient Specific ◽  
Inclusion Criteria ◽  
Total Hip ◽  
Inflammatory Drugs ◽  
Specific Factors ◽  
Anti Inflammatory ◽  
Meta Analyses

Aims The aim of this study was to assess the efficacy of non-selective and selective non-steroidal anti-inflammatory drugs (NSAIDs) in preventing heterotopic ossification (HO) after total hip arthroplasty (THA). Methods A thorough and systematic literature search was conducted and 29 studies were found that met inclusion criteria. Data were extracted and statistical analysis was carried out generating forest plots. Results Non-selective NSAIDs showed a significant decrease in the odds for forming HO after THA (odds ratio (OR) -1.35, confidence interval (CI) -1.83 to -0.86) when compared with placebo. Selective NSAIDs also showed a significant decrease in the odds for forming HO after THA when compared with placebo (OR -1.58, CI -2.41 to -0.75). When comparing non-selective NSAIDs with selective NSAIDs, there was no significant change in the odds for forming HO after THA (OR 0.22, CI -0.36 to 0.79). Conclusion Our meta-analyses of all available data suggest that both non-selective and selective NSAIDs are effective HO prophylaxis and can be used routinely after THA for pain control as well as prevention of HO. Indomethacin may serve as the benchmark among non-selective NSAIDs and celecoxib among selective NSAIDs. There was no difference in the incidence of HO between non-selective and selective NSAIDs, allowing physicians to choose either based on the clinical scenario and patient-specific factors. Cite this article: Bone Joint J 2018;100-B:915–22.

scholarly journals Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis

2013 ◽  
Vol 3 (4) ◽  
pp. 323 ◽  
Author(s):  
Siavash Jafari ◽  
Mahyar Etminan ◽  
Kourosh Afshar
Keyword(s):  
Prostate Cancer ◽  
Protective Effect ◽  
Journal Club ◽  
Meta Analysis ◽  
Cancer De La Prostate ◽  
Inclusion Criteria ◽  
Inflammatory Drugs ◽  
Observational Design ◽  
Anti Inflammatory ◽  
Significant Protective Effect

Prostate cancer is the most common visceral cancer in men. Manystudies have shown that nonsteroidal anti-inflammatory drugs(NSAIDs) may reduce the risk of prostate cancer. We systematicallysearched all relevant databases (MEDLINE, EMBASE, The CochraneCollaboration, CINAHL, Database of Abstracts of Review of Effectsand ACP Journal Club) to March 2008. We also explored bibliographiesof the articles, pertinent journals and conferences. Weselected relevant articles according to predefined inclusion criteriaby 2 independent reviewers. We used both fixed and randomeffectmodels for meta-analysis. We performed subgroup and sensitivityanalysis based on predefined variables. From 962 extractedarticles, 20 met the inclusion criteria with a total of 25 768 participants.All the studies had an observational design. There wasa statistically significant protective effect for NSAIDs on risk ofprostate cancer (odds ratio [OR] 0.92, 95% confidence interval[CI] 0.86–0.97). Subgroup analysis did not show any effect of studydesign or quality score on the results. There was a small but statisticallysignificant protective effect for acetylsalicylic acid (ASA)(OR 0.95, 95% CI 0.91–1.00). Exposure to non-ASA NSAIDs wasassociated with a slightly reduced likelihood of prostate cancer(OR 0.92, 95% CI 0.85–1.00). With the available data, we werenot able to determine an optimum dosage for NSAIDs. We concludethat taking NSAIDs may reduce the risk of prostate cancer.Nevertheless, the effect is small.Le cancer de la prostate est le cancer viscéral le plus fréquentchez l’homme. Bon nombre d’études ont montré que les antiinflammatoiresnon stéroïdiens (AINS) pouvaient réduire le risquede cancer de la prostate. Notre objectif était de réaliser une revuesystématique et une méta-analyse des articles publiés sur les effetsdes AINS dans la réduction du risque de cancer de la prostate.Toutes les bases de données pertinentes (MEDLINE, EMBASE,Collaboration Cochrane, CINAHL, Database of Abstracts of Reviewof Effects et ACP Journal Club) ont été systématiquement consultéesen mars 2008. On a également examiné la bibliographie des articlesdégagés et des revues et conférences pertinentes. Les articlespertinents ont été sélectionnés en fonction de critères d’inclusionprédéfinis par 2 analystes indépendants. Pour la méta-analyse,on a eu recours à des modèles à effets fixes et à effets aléatoires.Une analyse par sous-groupes et une analyse de sensibilité ont étéeffectuées à l’aide de variables prédéfinies. Sur les 962 articlesdégagés, 20 satisfaisaient aux critères d’inclusion, pour un totalde 25 768 sujets. Toutes les études étaient de type observationnel.On a noté un effet protecteur statistiquement significatif sur lerisque de cancer de la prostate avec les AINS (rapport de cotes de0,92; IC à 95 % de 0,86 à 0,97). L’analyse par sous-groupes n’arévélé aucun effet du plan de l’étude ou du score de qualité surles résultats. On a noté un effet protecteur léger mais tout de mêmesignificatif sur le plan statistique avec l’aspirine (RC 0,95; IC à95 % de 0,91 à 1,00). L’exposition à des AINS autres que l’aspirinea été associée à une probabilité légèrement moindre de cancer dela prostate (RC 0,92, IC à 95 % de 0,85 à 1,00). Les donnéesdisponibles ne nous ont pas permis de déterminer la posologieoptimale des AINS. Nous avons observé un effet favorable possibleassocié à la prise d’AINS dans la réduction du risque de cancerde la prostate, mais cet effet est minime.

Effects of Nonsteroidal Anti-inflammatory Drugs on Osseointegration: A Review

2015 ◽  
Vol 41 (2) ◽  
pp. 219-230 ◽  
Author(s):  
Francisco Isaac Fernandes Gomes ◽  
Maria Gerusa Brito Aragão ◽  
Vicente de Paulo Teixeira Pinto ◽  
Delane Viana Gondim ◽  
Francisco Cesar Barroso ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Dental Implants ◽  
Animal Studies ◽  
In Vitro Studies ◽  
Inclusion Criteria ◽  
Osteoprogenitor Cells ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory

The purpose of this study was to review the effects of nonsteroidal anti-inflammatory drugs on osseointegration and determine whether they cause failures in dental implants and whether patients who use them chronically can receive dental implants safely. A bibliographic electronic search was performed using the Cochrane Library, PubMed, and Medline databases, selecting articles published between January 1982 and December 2012. The search included the following keywords, either alone or combined: “nonsteroidal anti-inflammatory drugs,” “dental implants,” “bone healing,” and “osteoprogenitor cells.” The inclusion criteria were the following: randomized, double-blind, placebo-controlled clinical studies, in vivo animal model studies of osseointegration, and in vitro studies of the effects of these agents on osteoprogenitor cells. The literature search revealed 360 references. A total of 31 articles met the inclusion criteria, including 2 clinical trials, 20 animal studies, and 9 osteoprogenitor cell studies. The clinical trials revealed that cyclooxygenase-1 (COX-1) inhibitors did not impair osseointegration. The animal studies showed that any drug that is capable of inhibiting COX-2 may impair the osseointegration process. The in vitro studies showed that COX-2 inhibitors are the most potent depressors of osseointegration at the cellular level. Caution must be taken when selecting COX-2 nonsteroidal anti-inflammatory drugs during the postoperative period.

scholarly journals Nemszteroid gyulladáscsökkentő szerek a mozgásszervi fájdalom csillapításában

2019 ◽  
Vol 160 (22) ◽  
pp. 855-860
Author(s):  
Gábor Sütő
Keyword(s):  
Pain Control ◽  
Adverse Reactions ◽  
Cardiovascular Complications ◽  
Degenerative Disorders ◽  
Relieve Pain ◽  
Immune Mediated ◽  
Long Time ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract: Pain control in musculoskeletal disorders is still a challenging task. The most effective treatment of pain in autoimmune and immune-mediated diseases is the treatment of the disease itself. Analgesics, non-steroidal anti-inflammatory drugs and opioids are used to relieve pain. Analgesia is the central intervention of degenerative disorders. The most effective analgesic compounds are the non-steroidal anti-inflammatory drugs (NSAIDs). Concerns are raised regarding the safety of NSAIDs. There is not any organ which is not involved in adverse reactions, but the damage of the gastrointestinal system has been considered the most serious one for a long time. In the 21st century, the recognition of cardiovascular complications led to the re-evaluation of the role of these drugs in analgesia. Orv Hetil. 2019; 160(22): 855–860.

Nonsteroidal Anti-Inflammatory Drugs, Alone or Combined With Opioids, for Cancer Pain

2004 ◽  
Vol 22 (10) ◽  
pp. 1975-1992 ◽  
Author(s):  
Ewan McNicol ◽  
Scott Strassels ◽  
Leonidas Goudas ◽  
Joseph Lau ◽  
Daniel Carr
Keyword(s):  
Side Effects ◽  
Cancer Pain ◽  
Limited Data ◽  
Inclusion Criteria ◽  
Clinical Difference ◽  
Significant Difference ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Meta Analyses ◽  
Dose Dependent

Purpose To assess the safety and efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs), alone or combined with opioids, for the treatment of cancer pain. Patients and Methods Forty-two trials involving 3,084 patients met inclusion criteria: eight compared NSAID with placebo; 13 compared one NSAID with another; 23 compared NSAID with opioid, NSAID or opioid versus NSAID plus opioid combinations, or NSAID plus opioid combinations versus NSAID plus opioid combinations; and nine studies assessed the effect of increasing NSAID dose. Results Sixteen studies lasted 1 week or longer and 11 evaluated a single dose. Seven of eight trials demonstrated superior efficacy of single doses of NSAID compared with placebo. Only four of 13 studies reported increased efficacy of one NSAID compared with another; four other studies found that one NSAID had fewer side effects than one or more others. Thirteen of 14 studies found no difference, or minimal clinical difference, when comparing an NSAID plus opioid combination versus either drug alone. Comparisons between various NSAID plus opioid combinations were inconclusive. Four studies demonstrated increased efficacy with increased NSAID dose, without dose-dependent increases in side effects. Conclusion Heterogeneity of study methods and outcomes precluded meta-analyses. Short duration of studies undermines generalization of findings on efficacy and safety. On the basis of limited data, NSAIDs appear to be more effective than placebo for cancer pain; clear evidence to support superior safety or efficacy of one NSAID compared with another is lacking; and trials of combinations of an NSAID with an opioid have disclosed either no significant difference, or at most a slight but statistically significant advantage, compared with either single entity.

▾ Oral gold in rheumatoid arthritis

1988 ◽  
Vol 26 (18) ◽  
pp. 69.2-72
Keyword(s):  
Rheumatoid Arthritis ◽  
Lung Disease ◽  
Joint Damage ◽  
Relieve Pain ◽  
Systemic Manifestations ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Progressive Joint Damage

Rest, physiotherapy, simple analgesics and non-steroidal anti-inflammatory drugs (NSAIDS) may relieve pain, ease stiffness and reduce inflammation in rheumatoid arthritis (RA) but they do not arrest progressive joint damage nor are they effective against the systemic manifestations of RA (e.g. vasculitis, lung disease, amyloidosis).

scholarly journals Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents

2020 ◽  
Vol 11 ◽  
Author(s):  
Miriam Sobrino-García ◽  
Esther M. Moreno ◽  
Francisco J. Muñoz-Bellido ◽  
Maria T. Gracia-Bara ◽  
Elena Laffond ◽  
...  
Keyword(s):  
Scientific Evidence ◽  
Drug Hypersensitivity ◽  
Hypersensitivity Reactions ◽  
Inclusion Criteria ◽  
Beta Lactams ◽  
Drug Hypersensitivity Reactions ◽  
Clinical Consequences ◽  
Bibliographic Search ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Being labelled as allergic to different drugs results in patients receiving other treatments, which are more toxic, less effective and more expensive. We aimed to analyze different studies of the costs of drug hypersensitivity assessment.Methods: A bibliographic search on studies regarding this issue was performed, including the available scientific evidence up to June 2020. We searched three databases with terms related to costs and allergy testing in drug hypersensitivity reactions.Results: Our search revealed 1,430 publications, of which 20 met the inclusion criteria. In the manuscript, prospective studies evaluating the costs of the evaluation of patients with suspected allergy to beta-lactams or non-steroidal anti-inflammatory drugs are analyzed. Also, comment is made on the costs associated with incorrect labeling as non-steroidal anti-inflammatory drug or penicillin hypersensitivity.Conclusions: Taking all costs into account, the study of drug hypersensitivity is not expensive, particularly considering the economic and clinical consequences of labeling a patient with hypersensitivity to drugs.

Cannabis and Cannabinoids on Treatment of Inflammation: A Patent Review

2019 ◽  
Vol 13 (4) ◽  
pp. 256-267 ◽  
Author(s):  
Pedro Modesto Nascimento Menezes ◽  
Emanuella Chiara Valença Pereira ◽  
Maria Eduarda Gomes da Cruz Silva ◽  
Bismarques Augusto Oliveira da Silva ◽  
Luiz Antonio Miranda de Souza Duarte Filho ◽  
...  
Keyword(s):  
Physiological Response ◽  
Inflammatory Process ◽  
Inflammatory Responses ◽  
Synergistic Effects ◽  
Inclusion Criteria ◽  
Vast Number ◽  
Patent Review ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Do So

Background:The inflammatory process is a physiological response to a vast number of harmful stimulus that takes place in order to restore homeostasis. Many drugs used in pharmacotherapy are effective to control inflammatory responses, however, there is a range of adverse effects attributed to steroidal and non-steroidal anti-inflammatory drugs (NSAIDs). In this sense, herbal medicine and derivatives have gained more attention because of their effectiveness and safety, showing the importance of medicinal plants, especially the Cannabis genus and the cannabinoid derivatives.Objective:The aim of this prospection was to identify data related to patents involving Cannabis and cannabinoids for the treatment of inflammation.Method:To do so, a search for patents was conducted to evaluate the anti-inflammatory activity of Cannabis and cannabinoids. Four specialized databases for patent research were consulted using the terms "cannabis", "cannabidiol", "cannabinoids" and "THC" associated with "inflammation".Results:A total of 370 patents were found, of which 17 patents met the inclusion criteria. Although reports show synergistic effects of the plant components, patents involving Cannabis and cannabinoids focus on isolated substances (CBD e THC).Conclusion:However, patents related to Cannabis and cannabinoids are promising for future use of the plant or its derivatives on the treatment of inflammation.

Sign in / Sign up

Export Citation Format

Share Document